New obesity drug put to the heart safety test

NCT ID NCT07229157

Ongoing Disease control Sponsor: Amgen Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This early-stage trial is checking whether maridebart cafraglutide, a new weight-loss drug, affects the heart's electrical activity. About 81 adults with overweight or obesity will receive the drug or a placebo, and their heart rhythms will be closely monitored. The main goal is safety, not weight loss.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: maridebart cafraglutide (AMG 133)
What this could lead to: If successful, this study could show that maridebart cafraglutide is safe for the heart, supporting its development as a weight-loss treatment.
What could go wrong: This is a very early Phase 1 safety study with only 81 people. It is not designed to test weight loss, and the drug may still fail in later trials or have other side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for OBESITY are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Obesity obesity disorder Overweight

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

OBESITY OVERWEIGHT

Contacts and locations

Locations

Fortrea Clinical Research Unit - Dallas

Dallas, Texas, 75247-4968, United States
Fortrea Clinical Research Unit - Daytona Beach

Daytona Beach, Florida, 32117-5116, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.